Literature DB >> 2826656

Long-term persistent infection of macaque monkeys with the simian immunodeficiency virus.

M D Daniel1, N L Letvin, P K Sehgal, G Hunsmann, D K Schmidt, N W King, R C Desrosiers.   

Abstract

Juvenile rhesus macaques 6 to 18 months of age were experimentally infected by intravenous inoculation with the simian immunodeficiency virus (SIV), the T cell-tropic retrovirus of monkeys related to the human acquired immunodeficiency syndrome (AIDS) virus HIV. The SIV used for inoculation was grown either in normal human peripheral blood lymphocytes in the presence of interleukin 2 or in the human tumour cell line HUT-78. Eight of the macaques died 129 to 352 days post-inoculation with a variety of clinical and pathological findings paralleling those of AIDS in humans. However eight other animals became persistently infected for prolonged periods; these eight macaques remained alive at 537 and 820 days post-inoculation despite persistent lymphadenopathy and our continued ability to isolate SIV. The ability of these monkeys to survive infection correlated directly with the strength of their antibody response to SIV. Infection was also established in macaques using approximately 100 tissue culture infectious doses of HUT-78-grown SIV. There was no correlation between the dose of virus inoculum and either the strength of the antibody response or clinical outcome. These results demonstrate that SIV infection of macaques can be used not only to study acute AIDS but also to mimic the long-term persistent infection seen in carriers of HIV.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2826656     DOI: 10.1099/0022-1317-68-12-3183

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  60 in total

1.  Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus.

Authors:  C G Murphy; W T Lucas; R E Means; S Czajak; C L Hale; J D Lifson; A Kaur; R P Johnson; D M Knipe; R C Desrosiers
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

2.  Three-dimensional structures of soluble CD4-bound states of trimeric simian immunodeficiency virus envelope glycoproteins determined by using cryo-electron tomography.

Authors:  Tommi A White; Alberto Bartesaghi; Mario J Borgnia; M Jason V de la Cruz; Rachna Nandwani; James A Hoxie; Julian W Bess; Jeffrey D Lifson; Jacqueline L S Milne; Sriram Subramaniam
Journal:  J Virol       Date:  2011-09-21       Impact factor: 5.103

3.  Neutralizing antibodies modulate replication of simian immunodeficiency virus SIVmac in primary macaque macrophages.

Authors:  M F McEntee; M C Zink; M G Anderson; H Farzadegan; R J Adams; K A Kent; E J Stott; J E Clements; O Narayan
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

4.  Nuclear factors that bind two regions important to transcriptional activity of the simian immunodeficiency virus long terminal repeat.

Authors:  S Winandy; B Renjifo; Y Li; N Hopkins
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

5.  Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.

Authors:  P R Johnson; D C Montefiori; S Goldstein; T E Hamm; J Zhou; S Kitov; N L Haigwood; L Misher; W T London; J L Gerin
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

6.  Species-specific diversity among simian immunodeficiency viruses from African green monkeys.

Authors:  J S Allan; M Short; M E Taylor; S Su; V M Hirsch; P R Johnson; G M Shaw; B H Hahn
Journal:  J Virol       Date:  1991-06       Impact factor: 5.103

7.  Generation and characterization of infectious chimeric clones between human immunodeficiency virus type 1 and simian immunodeficiency virus from an African green monkey.

Authors:  R Shibata; H Sakai; T Kiyomasu; A Ishimoto; M Hayami; A Adachi
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

8.  9-(2-Phosphonylmethoxyethyl)-2,6-diaminopurine (PMEDAP): a novel agent with anti-human immunodeficiency virus activity in vitro and potent anti-Moloney murine sarcoma virus activity in vivo.

Authors:  L Naesens; J Balzarini; I Rosenberg; A Holý; E De Clercq
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

9.  Personality and serotonin transporter genotype interact with social context to affect immunity and viral set-point in simian immunodeficiency virus disease.

Authors:  John P Capitanio; Kristina Abel; Sally P Mendoza; Shelley A Blozis; Michael B McChesney; Steve W Cole; William A Mason
Journal:  Brain Behav Immun       Date:  2007-08-23       Impact factor: 7.217

10.  Early control of highly pathogenic simian immunodeficiency virus/human immunodeficiency virus chimeric virus infections in rhesus monkeys usually results in long-lasting asymptomatic clinical outcomes.

Authors:  Tatsuhiko Igarashi; Yasuyuki Endo; Yoshiaki Nishimura; Charles Buckler; Reza Sadjadpour; Olivia K Donau; Marie-Jeanne Dumaurier; Ronald J Plishka; Alicia Buckler-White; Malcolm A Martin
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.